A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

Center for Cancer and Blood Disorders, Bethesda

West Virginia University, Morgantown

University of North Carolina - Lineberger Comprehensive Cancer Center, Chapel Hill

University of Louisville Kentucky James Graham Brown Cancer Center, Louisville

University Hospitals of Cleveland, Cleveland

University of Arizona Cancer Center, Tucson, Tucson

Cedars-Sinai Medical Center (CSMC) - Samuel Oschin Comprehensive Cancer Institute, West Hollywood

University of California San Diego (UCSD) - Moores Cancer Center, La Jolla

Tufts Medical Center, Boston

Henry Ford Hospital, Detroit

NYU Langone Medical Center - NYU Medical Oncology Associates, New York

Queen Elizabeth II Health Sciences Centre, Halifax

McGill University - Jewish General Hospital, Montreal